Reviews |

Long-acting Inhaled β2-Agonists in Asthma Therapy FREE TO VIEW

Robert H. Moore; Ayesha Khan; Burton F. Dickey
Author and Funding Information

From the Baylor College of Medicine and the Houston Veterans Affairs Medical Center, Houston, Tex.

1998 by the American College of Chest Physicians

Chest. 1998;113(4):1095-1108. doi:10.1378/chest.113.4.1095
Text Size: A A A
Published online


Objective: To review the pharmacology of the long-acting inhaled β2-agonists, salmeterol and formoterol, summarize results of their clinical trials, evaluate their safety records, and discuss their roles in the treatment of asthma.

Data sources: Preclinical and clinical studies involving salmeterol or formoterol were identified by a MEDLINE search, weekly computerized literature updates, and manual searches. Studies of satisfactory quality were chosen for review.

Data synthesis: Salmeterol and formoterol are potent and selective β2-adrenoceptor agonists with durations of action >12 h. Their major differences are that formoterol has a rapid onset of action and is a partial agonist of high intrinsic efficacy, whereas salmeterol has a delayed onset and is a partial agonist of low intrinsic efficacy. Twice daily use of either drug results in improved lung function, reduced symptoms, and a better quality of life. These agents protect against exercise-induced asthma for 12 h and eliminate nighttime awakening in most patients. Limited tolerance develops, especially to their bronchoprotective effects, but their improvement of lung function is sustained.

Conclusions: Regular use of salmeterol or formoterol provides subjective and objective amelioration of asthma in patients experiencing excessive symptoms or physiologic impairment despite the regular administration of low doses of inhaled corticosteroids (equivalent to approximately 500 µg/d of beclomethasone). Intermittent use of either long-acting β2-agonist can provide prolonged protection against exercise-induced asthma or nighttime symptoms. Patients should be instructed to continue taking inhaled steroids when long-acting β2-agonists are administered on a regular schedule and to not take long-acting β2-agonists between regularly scheduled doses. Used properly, they are effective and safe adjunctive agents in the treatment of asthma.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Theophylline. Pharmaceuticals (Basel) 2010;3(3):725-747.
Beta-Adrenergic Agonists. Pharmaceuticals (Basel) 2010;3(4):1016-1044.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543